Free Trial

Dyne Therapeutics (DYN) Stock Price, News & Analysis

-1.78 (-5.03%)
(As of 01:58 PM ET)
Today's Range
50-Day Range
52-Week Range
1.43 million shs
Average Volume
1.80 million shs
Market Capitalization
$2.94 billion
P/E Ratio
Dividend Yield
Price Target

Dyne Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.11 Rating Score
19.0% Upside
$40.78 Price Target
Short Interest
18.91% of Float Sold Short
Dividend Strength
News Sentiment
0.38mentions of Dyne Therapeutics in the last 14 days
Based on 38 Articles This Week
Insider Trading
Selling Shares
$32.59 M Sold Last Quarter
Proj. Earnings Growth
From ($3.10) to ($3.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.20 out of 5 stars

Medical Sector

605th out of 921 stocks

Pharmaceutical Preparations Industry

277th out of 419 stocks

DYN stock logo

About Dyne Therapeutics Stock (NASDAQ:DYN)

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

DYN Stock Price History

DYN Stock News Headlines

Announcement of The Shaw Laureates 2024
Dyne Therapeutics (NASDAQ:DYN) Shares Gap Up on Analyst Upgrade
Dyne Therapeutics Shares Rise 23% on Favorable Drug Data
See More Headlines
Receive DYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
9 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$1.49 per share


Free Float
Market Cap
$2.90 billion
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

DYN Stock Analysis - Frequently Asked Questions

Should I buy or sell Dyne Therapeutics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DYN shares.
View DYN analyst ratings
or view top-rated stocks.

What is Dyne Therapeutics' stock price target for 2024?

9 Wall Street research analysts have issued 12-month price targets for Dyne Therapeutics' stock. Their DYN share price targets range from $22.00 to $56.00. On average, they predict the company's share price to reach $40.78 in the next year. This suggests a possible upside of 19.0% from the stock's current price.
View analysts price targets for DYN
or view top-rated stocks among Wall Street analysts.

How have DYN shares performed in 2024?

Dyne Therapeutics' stock was trading at $13.30 at the beginning of the year. Since then, DYN shares have increased by 157.7% and is now trading at $34.27.
View the best growth stocks for 2024 here

When is Dyne Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our DYN earnings forecast

How were Dyne Therapeutics' earnings last quarter?

Dyne Therapeutics, Inc. (NASDAQ:DYN) issued its earnings results on Thursday, May, 2nd. The company reported ($0.81) EPS for the quarter, meeting the consensus estimate of ($0.81).

When did Dyne Therapeutics IPO?

Dyne Therapeutics (DYN) raised $175 million in an initial public offering (IPO) on Thursday, September 17th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel served as the underwriters for the IPO.

Who are Dyne Therapeutics' major shareholders?

Dyne Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Atlas Venture Life Science Advisors LLC (9.18%), RA Capital Management L.P. (5.67%), Vanguard Group Inc. (3.94%), Janus Henderson Group PLC (3.06%), Vivo Capital LLC (1.90%) and Artal Group S.A. (1.74%). Insiders that own company stock include Dirk Kersten, Jason P Rhodes, Jonathan Mcneill, Joshua T Brumm, Oxana Beskrovnaya, Richard William Scalzo, Susanna Gatti High, Venture Fund Xi LP Atlas and Wildon Farwell.
View institutional ownership trends

How do I buy shares of Dyne Therapeutics?

Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DYN) was last updated on 5/21/2024 by Staff

From Our Partners